LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced that it will be featured as a presenting company at the Roth Capital Partners 29th Annual Conference and at the Oppenheimer 27th Annual Healthcare Conference.
The Roth Capital Partners Conference is being held on March 12-17th at The Ritz Carlton hotel in Dana Point, CA. The Company will present a corporate overview on Tuesday, March 14th at 10:00 am Pacific Time in PINK Salon 5 and will be available to participate in one-on-one meetings with investors.
The 27th Annual Oppenheimer Healthcare Conference will be held on March 21-22th at the Westin Hotel New York Grand Central in New York City. The Company will present a corporate overview on Tuesday, March 21st at 1:00 pm Eastern Time in the Ambassador Room and will be available to participate in one-on-one meetings with investors. The presentation at the Oppenheimer conference will be webcast live. To access the Oppenheimer webcast, please visit the following link https://www.veracast.com/webcasts/opco/healthcare2017/26108161893.cfm. The webcast replay will remain available for 90 days following the live presentation.
About Poxel SA
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
Jonae R. Barnes, +1-617-818-2985
Senior Vice President, Investor Relations and Public Relations
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May, + 49 89 2424 3494 or + 49 175 571 1562
Investor relations / Media - France
Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55
Source: Poxel SA
Released March 9, 2017